June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Jason S Slakter
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Hanna R. Coleman
    Columbia University Irving Medical Center, New York, New York, United States
  • Charles Clifton Wykoff
    Retina Consultants of Texas, Houston, Texas, United States
  • Clare Price
    Opthea Limited, Melbourne, Victoria, Australia
  • Megan E. Baldwin
    Opthea Limited, Melbourne, Victoria, Australia
  • Timothy L Jackson
    King’s Ophthalmology Research Unit, Faculty of Life Sciences and Medicine, King’s College London, London, UK, United Kingdom
  • Footnotes
    Commercial Relationships   Jason Slakter Apellis, Opthea, Ltd., Regeneron, AstraZenica, Code C (Consultant/Contractor), Mylan, Sanofi, Apellis, Aerie, Regeneron, Johnson & Johnson, Amgen, Aura, Asclepix, QED Therapeutics, Opthea, Ltd, Eyepoint, Inozyme, Roche, Code F (Financial Support), Apellis, Code I (Personal Financial Interest); Hanna Coleman None; Charles Wykoff Adverum, Aerie, Aerpio, Alimera Sciences, Allegro, Allergan Inc, Allgenesis, Alnylam, Apellis, Arrowhead, Bausch & Lomb, Bayer Healthcare, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies, Clearside Biomedical, Inc, DORC, EyePoint, Genentech/Roche, Gyroscope, Ionis, Iveric Bio, Janssen, Kato, Kodiak, Long Bridge Medical, NGM, Notal Vision, Novartis (US and AG Basel), OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea Limited, Palatin, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Roche, Santen, Surrozen, Takeda, Verana Heath, Vitranu , Code C (Consultant/Contractor), Adverum, Aerie, Aerpio, Allergan, Amgen, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnologies, Clearside, Biomedical, EyePoint, Gemini, Genentech/Roche, Graybug Vision, Gyroscope, Ionis, iRENIX, Iveric Bio, LMRI, Neurotech, Novartis (US and AG Basel), NGM, Novartis, Opthea, Oxurion, RecensMedical, Regeneron, Regenxbio, Roche, SamChunDang, Samsung Bioepis, Santen, Taiwan Liposome Company, Xbrane BioPharma., Code F (Financial Support); Clare Price Opthea, Ltd., Code E (Employment), Opthea, Ltd., Code I (Personal Financial Interest); Megan Baldwin Opthea, Ltd., Code E (Employment), Opthea, Ltd., Code I (Personal Financial Interest); Timothy Jackson 2CTech, Allergan, iLumen, Allegro, Alcon, Opthea Ltd, Oxurion, Code C (Consultant/Contractor), Opthea, Ltd., Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 382 – F0213. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jason S Slakter, Hanna R. Coleman, Charles Clifton Wykoff, Clare Price, Megan E. Baldwin, Timothy L Jackson; Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2022;63(7):382 – F0213.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Vascular endothelial growth factor-C and D (VEGF-C/-D) are angiogenic mediators which may contribute to treatment escape with VEGF-A suppression of retinal disease. The aim of this investigation was to assess combination therapy of OPT-302 (anti-VEGF-C/-D) with ranibizumab (anti-VEGF-A) for the treatment of polypoidal choroidal vasculopathy (PCV).

Methods : Prespecified subgroup analysis of a Phase 2b, randomized, sham-controlled study of OPT-302 administered to treat neovascular age-related macular degeneration (NCT03345082). Participants in the subgroup analysis had PCV identified in the study eye by masked readers at a central reading center. Polyps were identified and defined using multimodal imaging, including fundus photography (subretinal orange nodules), fluorescein angiography (typical primarily occult multifocal lesions) and spectral domain optical coherence tomography (notched, sharply peaked or multi-lobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border). Eyes were randomized to receive 6-monthly intravitreal injections of either ranibizumab (0.5 mg) + OPT-302 (0.5 mg or 2 mg) or ranibizumab + sham. Outcomes measures included best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA), anatomic changes, and safety / tolerability.

Results : Sixty-six participants with PCV were included. OPT-302 with ranibizumab was well tolerated, consistent with the full study population, with no clinically significant safety findings. The mean BCVA change from baseline to week 24 showed a dose response in participants with PCV, who gained 13.5 letters in the 2 mg OPT-302 combination group (n = 22), 10.9 letters in the 0.5 mg OPT-302 combination group (n = 24) and 6.9 letters in the ranibizumab control group (n = 20). The +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy over ranibizumab (p = 0.0253) was accompanied by a greater proportion of participants gaining ≥ 10 or ≥ 15 letters, fewer losing ≥ 5 letters and fewer with retinal fluid at week 24.

Conclusions : OPT-302 combination therapy was well tolerated, with greater improvements in BCVA and less retinal fluid compared to ranibizumab monotherapy in participants with symptomatic macular PCV. Larger studies of dual inhibition of VEGF-C/-D and VEGF-A for the treatment of PCV are warranted.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.